BIOQUAL, INC.
- ROCKVILLE, MD 20850-3336
- bioqual.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $64.6M
- Awards on record
- 12
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
BIOQUAL, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About BIOQUAL, INC.
- Headquarters
- ROCKVILLE, MD 20850-3336
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEICK9LGQ7EBNN8
- CAGE059B4
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $64.6M
- Awards on record
- 12
- Top funding agencies
- National Institutes of Health
Awards
75N93019C00069
Recompete < 6 mo: Potential end Mar 27, 2027 (4 months away)ANIMAL CARE AND LABORATORY SUPPORT SERVICES TO THE VACCINE RESEARCH CENTER
Department of Health and Human Services · National Institutes of Health
- Obligated
- $64.4M
- Period of performance
- Sep 28, 2019 – Mar 27, 2027
75N94024P00327
Completed: Period of performance ended Jun 4, 2025NIDDK: SEVERABLE - ACQUISITION OF SERVICES FOR HUMANIZED MICE STUDIES
Department of Health and Human Services · National Institutes of Health
- Obligated
- $195.3K
- Period of performance
- Jun 5, 2024 – Jun 4, 2025
75N94022P00763
Completed: Period of performance ended Sep 15, 2023NIDDK - ACQUISITION OF SERVICES FOR THE RAT TREATMENT STUDY
Department of Health and Human Services · National Institutes of Health
- Obligated
- $20.6K
- Period of performance
- Sep 16, 2022 – Sep 15, 2023
75N94022P00775
Completed: Period of performance ended Sep 15, 2023LAB ANALYSIS FOR NIDDK MICE STUDIES AS OUTLINED IN QUOTES #BQL-22-27 AND #NDDK-22-04 BILL MONTHLY IN ARREARS.
Department of Health and Human Services · National Institutes of Health
- Obligated
- $89.3K
- Period of performance
- Sep 16, 2022 – Sep 15, 2023
75N91023P00503
Completed: Period of performance ended Sep 3, 2023SARS-COV-2 HAMSTER STUDY - FOR PAYMENT ONLY PO
Department of Health and Human Services · National Institutes of Health
- Obligated
- $0
- Period of performance
- Aug 4, 2023 – Sep 3, 2023
75N94023P00401
Completed: Period of performance ended Jun 28, 2023NIDDK / RAT TREATMENT STUDY
Department of Health and Human Services · National Institutes of Health
- Obligated
- $15.2K
- Period of performance
- May 26, 2023 – Jun 28, 2023
75N93018F00003
Completed: Period of performance ended Sep 30, 2020TASK B05. 09/24/2018 - 11/23/2019.
Department of Health and Human Services · National Institutes of Health
- Obligated
- $2.7M
- Period of performance
- Aug 28, 2018 – Sep 30, 2020
HHSN272201300003I-HHSN27200001
Completed: Period of performance ended Apr 30, 2020IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $4.4M
- Period of performance
- May 1, 2013 – Apr 30, 2020
HHSN272201300003I-HHSN27200002
Completed: Period of performance ended Apr 30, 2020IGF::OT::IGF SIMAIN VACCINE EVALUATION UNITS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $1.5M
- Period of performance
- May 1, 2013 – Apr 30, 2020
HHSN272201300003I-HHSN27200014
Completed: Period of performance ended Mar 31, 2020IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $294.8K
- Period of performance
- Aug 25, 2017 – Mar 31, 2020
HHSN272201300003I-HHSN27200010
Completed: Period of performance ended Aug 14, 2019IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $2.2M
- Period of performance
- Apr 15, 2016 – Aug 14, 2019
HHSN272201300003I-HHSN27200012
Completed: Period of performance ended Apr 30, 2019IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $608.4K
- Period of performance
- May 1, 2016 – Apr 30, 2019
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N93019C00069 ANIMAL CARE AND LABORATORY SUPPORT SERVICES TO THE VACCINE RESEARCH CENTER | Department of Health and Human Services · National Institutes of Health | 541715 · AN91R&D- MEDICAL: OTHER (BASIC RESEARCH) | $64.4M | Sep 28, 2019 – Mar 27, 2027 | Recompete < 6 mo: Potential end Mar 27, 2027 (4 months away)AI brief for award 75N93019C00069Bid team for the recompete of award 75N93019C00069 |
75N94024P00327 NIDDK: SEVERABLE - ACQUISITION OF SERVICES FOR HUMANIZED MICE STUDIES | Department of Health and Human Services · National Institutes of Health | 541380 · Q301REFERENCE LABORATORY TESTING | $195.3K | Jun 5, 2024 – Jun 4, 2025 | Completed: Period of performance ended Jun 4, 2025 |
75N94022P00763 NIDDK - ACQUISITION OF SERVICES FOR THE RAT TREATMENT STUDY | Department of Health and Human Services · National Institutes of Health | 541380 · Q301REFERENCE LABORATORY TESTING | $20.6K | Sep 16, 2022 – Sep 15, 2023 | Completed: Period of performance ended Sep 15, 2023 |
75N94022P00775 LAB ANALYSIS FOR NIDDK MICE STUDIES AS OUTLINED IN QUOTES #BQL-22-27 AND #NDDK-22-04 BILL MONTHLY IN ARREARS. | Department of Health and Human Services · National Institutes of Health | 541715 · Q301REFERENCE LABORATORY TESTING | $89.3K | Sep 16, 2022 – Sep 15, 2023 | Completed: Period of performance ended Sep 15, 2023 |
75N91023P00503 SARS-COV-2 HAMSTER STUDY - FOR PAYMENT ONLY PO | Department of Health and Human Services · National Institutes of Health | 541990 · Q301REFERENCE LABORATORY TESTING | $0 | Aug 4, 2023 – Sep 3, 2023 | Completed: Period of performance ended Sep 3, 2023 |
75N94023P00401 NIDDK / RAT TREATMENT STUDY | Department of Health and Human Services · National Institutes of Health | 541380 · Q301REFERENCE LABORATORY TESTING | $15.2K | May 26, 2023 – Jun 28, 2023 | Completed: Period of performance ended Jun 28, 2023 |
75N93018F00003 under HHSN272201700015I TASK B05. 09/24/2018 - 11/23/2019. | Department of Health and Human Services · National Institutes of Health | 541711 · AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $2.7M | Aug 28, 2018 – Sep 30, 2020 | Completed: Period of performance ended Sep 30, 2020 |
HHSN272201300003I-HHSN27200001 under HHSN272201300003I IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS | Department of Health and Human Services · National Institutes of Health | 541712 · AN81R&D- MEDICAL: AIDS RESEARCH (BASIC RESEARCH) | $4.4M | May 1, 2013 – Apr 30, 2020 | Completed: Period of performance ended Apr 30, 2020 |
HHSN272201300003I-HHSN27200002 under HHSN272201300003I IGF::OT::IGF SIMAIN VACCINE EVALUATION UNITS | Department of Health and Human Services · National Institutes of Health | 541712 · AN81R&D- MEDICAL: AIDS RESEARCH (BASIC RESEARCH) | $1.5M | May 1, 2013 – Apr 30, 2020 | Completed: Period of performance ended Apr 30, 2020 |
HHSN272201300003I-HHSN27200014 under HHSN272201300003I IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS | Department of Health and Human Services · National Institutes of Health | 541712 · AN81R&D- MEDICAL: AIDS RESEARCH (BASIC RESEARCH) | $294.8K | Aug 25, 2017 – Mar 31, 2020 | Completed: Period of performance ended Mar 31, 2020 |
HHSN272201300003I-HHSN27200010 under HHSN272201300003I IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS | Department of Health and Human Services · National Institutes of Health | 541712 · AN81R&D- MEDICAL: AIDS RESEARCH (BASIC RESEARCH) | $2.2M | Apr 15, 2016 – Aug 14, 2019 | Completed: Period of performance ended Aug 14, 2019 |
HHSN272201300003I-HHSN27200012 under HHSN272201300003I IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS | Department of Health and Human Services · National Institutes of Health | 541712 · AN81R&D- MEDICAL: AIDS RESEARCH (BASIC RESEARCH) | $608.4K | May 1, 2016 – Apr 30, 2019 | Completed: Period of performance ended Apr 30, 2019 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 13 awards
- Total awarded
- $2,127,952
- By phase
- SBIR Phase I: 10
- SBIR Phase II: 3
- By agency
- Department of Health and Human Services: 13
- By year
- 2001: 2
- 2000: 2
- 1998: 1
- 1997: 3
- 1986: 2
- 1985: 1
- 1984: 1
- 1983: 1
Awards (most recent first)
Comparative DNA Sequence Variation in Alzheimer Genes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2001 · $0
Comparative DNA Sequence Variation in Alzheimer Genes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2001 · $382,614
Not Available
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2000 · $99,153
Not Available
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2000 · $98,711
COMPARATIVE NEUROBIOLOGY OF AGING RESOURCE
SBIR Phase II · Department of Health and Human Services · 1998 · $753,144
COMPARATIVE NEUROBIOLOGY OF AGING RESOURCE
SBIR Phase I · Department of Health and Human Services · 1997 · $93,916
NONHUMAN PRIMATE MODEL FOR HELICOBACTER PYLORI INFECTION
SBIR Phase I · Department of Health and Human Services · 1997 · $100,000
IDENTIFICATION OF H PYLORI PROTECTIVE ANTIGENS
SBIR Phase I · Department of Health and Human Services · 1997 · $99,673
IN 1972, THE CHINESE ISOLATED AND CHARACTERIZED ARTEMISININ,AN ANTIMALARIAL DRUG PRESENT IN THE CHINESE HERB QINGHAO (ARTEMISIA ANNUA).
SBIR Phase I · Department of Health and Human Services · 1986 · $50,000
DIZYGOTIC MOSAIC ANIMALS (CHIMERAS, ALLOPHENICS) ARE EXPERIMENTALLY PRODUCED BY AMALGAMATING PREIMPLANTATION EMBRYONIC TISSUES.
SBIR Phase I · Department of Health and Human Services · 1986 · $49,000
DURING THE PAST DECADE, MARIJUANA USE HAS INCREASED DRAMATICALLY AT ALL AGE LEVELS.
SBIR Phase I · Department of Health and Human Services · 1985 · $48,970
DEVELOPMENT MONOCLONAL ANTIBODIES TO GOSSYPOL - PHASE I
SBIR Phase II · Department of Health and Human Services · 1984 · $305,701
DEVELOPMENT MONOCLONAL ANTIBODIES TO GOSSYPOL - PHASE I
SBIR Phase I · Department of Health and Human Services · 1983 · $47,070
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)Primary
- 541713Research and Development in NanotechnologySmall business under this code’s size standard
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard
SAM.gov reports this entity as small under 2 of 3 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with BIOQUAL, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
